slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 6,841-6,870
Pages 395
Rows per page 30
Slide function
6,841-6,870 of 11,828
46
Includes two sets of charts: tumor volume over time and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
55
The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient administration model.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
11
The slide uses a consistent color palette to distinguish business segments and financial metrics across three distinct bar charts.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · FinancialsLoop · Pattern Hunter1 hit
12
The slide uses a series of bar charts to display performance trends over five quarters (3Q22 to 3Q23).Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · FinancialsLoop · Pattern Hunter1 hit
18
The slide uses a dual-column layout: a table for AUM breakdown and a horizontal timeline for historical growth milestones.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · Solution1 hit
23
LTM refers to the last twelve months as of September 30, 2023.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · Solution1 hit
11
Slide highlights a strategic partnership/supply agreement as a form of business traction.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
15
The slide highlights that THIO has a better safety profile than standard chemotherapy, which typically has 70-80% incidence of Grade 3-5 side effects.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
17
Data presented in a table format with specific clinical definitions for DCR and treatment lines.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
24
The slide presents two line charts showing tumor volume reduction and long-term survival/rechallenge success.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
28
The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC mouse models.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
29
The chart shows a clear divergence between the control group (increasing tumor volume) and the THIO group (decreasing tumor volume to near zero).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
39
The slide serves as a milestone marker for the company's public listing.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
09
The slide uses a 3-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
13
The slide uses a horizontal timeline to contrast current (2023-2024) and future (2024-2025) clinical trial phases.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
14
The slide features a thumbnail of a scientific poster presentation.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
09
The slide uses a 3-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Traction1 hit
15
The slide features a thumbnail of a scientific poster presentation.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
05
The slide uses a process flow diagram to show the funnel from potential partnerships to active clinical programs.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · Traction1 hit
06
The chart shows a cumulative growth of partnerships over time from 2017 to 2023.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · Traction1 hit
14
The slide uses donut charts to visualize the distribution of milestone events across IND, Pre-Pivotal, and Pivotal or Later phases.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations 1 hit
16
The diagram uses concentric circles to represent clinical phases and color-coded dots to represent cell approaches (allogeneic vs autologous).MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations 1 hit
17
The slide uses a Vitruvian Man-style graphic to represent the breadth of therapeutic applications.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations 1 hit
06
Nemaura Medical | Investor Presentation Deck | 19 slidesNemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations Beat · Traction1 hit
07
The slide presents two line charts: one comparing BGM vs Invasive CGM, and one showing raw sugarBEAT data.Nemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations Beat · Traction1 hit
06
The slide uses a consistent three-column layout to compare key performance metrics across three distinct game titles.Nexters | Investor Presentation Deck | 18 slides · GDEV
Pitch deck Investor relations 1 hit
08
Includes growth percentage annotations between 2020 and 2022 for each metric.Nexters | Investor Presentation Deck | 18 slides · GDEV
Pitch deck Investor relations 1 hit
13
The slide uses dot plots to show IC50 values for different drugs across fusion partners and mutations, and a bar chart to show tumor regression efficacy.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit